A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunomodulator to an associated sterile container, the associated sterile container having a defined volume of diluted immunomodulator after dilution thereof, providing a viscous encapsulation material, selecting a prescribed amount of concentrated immunomodulator, the prescribed amount defined as that amount of the diluted immunomodulator extract required to provide a number of doses equal to the number of dispensable increments from the container containing the viscous encapsulation material, introducing the selected amount of each of the diluted immunomodulator extract into the viscous encapsulation material, introducing an amount of imiquimod into the viscous encapsulation material, and mixing the introduced amount of each of the diluted immunomodulator extracts and the introduced amount of imiquimod with the viscous encapsulating material.

Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

The disclosure generally relates to tamper-resistant transdermal dosage forms. The dosage forms can comprise an active agent and more than one antagonist reservoir.

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

A transdermal device is provided. The transdermal device includes a transdermal patch, a sheet-shaped electrode stacked overlying one surface of the transdermal patch, and a power source connected to the sheet-shaped electrode. The transdermal patch includes a carrier layer. The carrier layer comprises a hollow structure and an external composition. The hollow structure comprises a plurality of cells partitioned by an insulator and has hollow portions penetrating through one plane surface to the other plane surface of the hollow structure. The external composition comprises a dispersion liquid comprising a nanoparticle containing an active ingredient.

Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

The present invention relates to a solid pharmaceutical dosage form for abusable drug delivery with reduced illicit abuse potential. The dosage form is presented as a bioerodable transmucosal delivery device that includes an abusable drug and an antagonist to the abusable drug associated with an abuse-resistant matrix. The devices of the invention may be in the form of a layered film or a tablet. Upon application in a non-abusive manner, the device adheres to the mucosal surface, providing transmucosal drug delivery of the drug with minimal absorption of the antagonist into systemic circulation.

A face mask or body cover assembly, including for lips, can include a band and a lip-contacting portion comprising a plurality of plastic liners, a skin healing formulation, and an ice pack gel solution filling. The face mask assembly can self-adhere to a patient's face. The skin healing formulation can include a first active botanical compound and a second active botanical compound that can function as an analgesic, an antimicrobial, an activity, an anti-inflammatory and/or an antioxidant.

This invention relates to an activated charcoal patch, which can be applied on a user's skin. The activated charcoal patch includes a hydrogel with activated charcoal particles dispersed therein. Upon applying the activated charcoal patch, the activated charcoal particles in the hydrogel absorb or extract the pathogens, toxic chemicals, inflammatory mediators and other undesired radicals from the skin. Also included within the scope of the invention are bioactive agents, such as insect repellants, sun screens, cosmetic agents, etc.